{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-3.0","upperLimit":"0.0","value":"-1.00"}]}],"title":"Month 3"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-6.0","upperLimit":"2.0","value":"-2.00"}]}],"title":"Month 6"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-6.0","upperLimit":"1.0","value":"-2.00"}]}],"title":"Month 9"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-6.0","upperLimit":"1.0","value":"-2.00"}]}],"title":"Month 12"}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"}],"units":"Participants"}],"description":"Change of clinical signs from baseline: ring size. In Japan, ring sizes are specified using a numerical scale, that only has whole sizes, and does not have simple linear correlation with diameter or circumference. Only numbers are used ranging from 1 to 27. For instance, a ring size of 1 in Japan is equivalent to an inside circumference ring size of 38.86 mm and a ring size of 27 in Japan is equivalent to an inside circumference ring size of 70.15 mm.","dispersionType":"Full Range","groups":[{"description":"All patients randomized regardless of pasireotide LAR dose.","id":"OG000","title":"Pasireotide LAR - All Participants"}],"paramType":"MEDIAN","populationDescription":"FAS: Comprises all patients to whom study treatment has been assigned by randomization. Protocol allowed to change treatment dose (eg, 20mg -\\> 40mg -\\>20mg -\\> 40mg -\\>60mg) based on efficacy and safety after 3month treatment. So we combined Arms/groups.","reportingStatus":"POSTED","timeFrame":"Baseline, Months 3, 6, 9, 12","title":"Change in Ring Size From Baseline","type":"SECONDARY","unitOfMeasure":"other - Japanese ring size number"}